Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: EC:3.4.21.73 (urokinase-type plasminogen activator)
 10,685 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

By means of serial investigations of coronary angiographies and acute dissections in the acute myocardial infarction (AMI) in the vast majority of the patients fresh thrombi could be made evident as cause of the vascular occlusion. By lysins produced within the body parts of the thrombi can be lyzed (spontaneous lysis up to 20%). However, thrombolytically effective substances considerably increase the recanalization in the first hours after the beginning of the symptomatology. These substances with clinical significance are as follows: streptokinase (SK), urokinase, tissue plasminogen activator (TPA) and acylated streptokinase (APSAC). The broad application of the thrombolytic therapy (TT) is possible only by the intravenous, highly dosed short-term method and demands non-invasive parameters for the judgment of effectiveness [(ECG, ejection fraction globally (EFg), marker protein monitoring)]. Though the ECG allows only conditionedly quantitative statements concerning the size of the myocardial infarction, an estimation of the successful TT in sufficient early recanalization is possible by a dynamics of criterias of ECG and electrocardiographic signs are less distinctly expressed, respectively. The limitation of the size of the myocardial infarction by the successful reperfusion which finds its expression in the remaining left-ventricular function is the decisive link for the influence on the quality of the life and the prognosis of these patients. A dynamics of the ejection fraction globally in the effective thrombolytic therapy is to be expressed. For this purpose at least two single measurements (acute phase, control 1st and 2nd week) are necessary. A non-invasive monitoring of marker proteins (enzymes/isoenzymes: CK, CK-MB, LDH and myoglobin, respectively) is suitable for the recognition of the effective thrombolytic therapy.(ABSTRACT TRUNCATED AT 250 WORDS)
 ...
PMID:[Thrombolytic therapy in acute myocardial infarct. 1. Markers for evaluating effectiveness and thrombolytic substances]. 219 13

A case of microangiopathic hemolytic anemia (MHA) associated with the immunosuppressive agent, cyclosporine, is reported herein. The patient manifested anemia with red blood cell fragmentation, hypertension, thrombocytopenia, elevation of serum LDH levels and glomerular capillary thromboses within a few days of his transplantation. Extensive treatments with urokinase and heparin proved ineffective and graftectomy was performed 7 days after his transplantation. Immunofluorescent staining failed to show immunoglobulin (IgG or IgM) or complement (C3) deposition within the glomeruli, which discriminated MHA from acute humoral-vascular rejection.
 ...
PMID:Cyclosporine-associated microangiopathic hemolytic anemia in a renal transplant recipient. 265 53

The cardiac function and the effect of therapy in patients with acute myocardial infarction (AMI) were assessed in over 100 patients by analysis of 201Tl-scintigraphy and 99mTc-gated pool study in our ICU. The cardiac function and 201Tl-defect ratio were compared with the results obtained in chronic phase. Sixteen of them were treated with intravenous urokinase (UK) within 6 hours from onset. The other 18 patients without UK treatment served as a control group. Significant correlation was recognized between 201Tl-defect ratio and peak-CPK levels, peak-GOT levels, peak-LDH levels. Significant correlation (r = -0.655, r = -0.713) were found between 201Tl-defect ratio and LVEF in acute and chronic phase. The UK group showed a significant increase of LVEF as compared with the control group in patients with antero-septal (A/S) AMI. In inferior (INF) AMI, no significant differences were observed UK and control group in LVEF, RVEF and 201Tl-defect ratio. In chronic phase, improvements of LVEF and 201Tl-defect ratio were observed in patients with A/S AMI. But no significant differences of LVEF, RVEF and 201Tl-defect ratio were observed in A/S AMI in acute and chronic phase. The UK group showed a significant increase of LVEF (50.1%) as compared with the control group of A/S AMI in chronic phase. We have demonstrated that a combination of 201Tl-scintigraphy and 99mTc-gated pool study are useful techniques in ICU, to evaluate the cardiac function and the effect of thrombolysis therapy and thus greatly contribute to the primary care of AMI cases.
 ...
PMID:[The evaluation of cardiac function and the effect of therapy in acute myocardial infarction--comparison by radio nuclide method in acute and chronic phase]. 350 Nov 35

The effects of the intravenous administration of hyaluronidase (HY; 2,500 IU/kg) and urokinase (UK; 20,000 and 40,000 IU/kg), alone or in combination, on the isoproterenol (ISP) induced myocardial infarction (MI) in rats, were studied. The severity of infarction was determined by measuring the levels of serum enzymes (CPK, GOT, LDH) and by evaluating the extent of the injured areas and the incidence of mortality. Plasma thromboxane B2 (TXB2) levels were also determined. All the treatments reduced the infarction area and the enzyme levels (increased by ISP) to a varying degree. However, a definite potentiating activity was obtained when HY was combined with the highest dose of UK. This combination was also capable of reducing the mortality rate. Finally, both HY and UK or the combined preparation brought the plasma TXB2 levels back to normal. These findings suggest the possibility of complementary activities of HY and UK in the treatment of experimental MI.
 ...
PMID:The co-operative action of hyaluronidase and urokinase on the isoproterenol-induced myocardial infarction in rats. 371 99

To lyse intracoronary (IC) thrombi, coronary angiography was performed for 36 patients with acute myocardial infarction who were admitted within 12 hours of the onset of symptoms. Their average age was 59.6 years. Twenty-four patients (66.7%) had total occlusions of the infarct-related coronary artery, and 12 patients (33.3%) had severe atherosclerotic stenosis without occlusion (group A = Stenosis). In 19 of the 24 patients (79.2%) with total occlusion, IC infusion of urokinase (UK) at a rate of 500 units/kg/min during 10 to 20 min resulted in reperfusion of the distal coronary artery (group B = Thrombolysis). In the remaining five patients, IC thrombolysis was not successfully performed (group C = No effect). The degree of coronary artery stenosis immediately after reperfusion was 88.7 +/- 18.8% in group B. Long-term follow-up (four weeks) coronary angiography in groups A and B revealed improved patency to 79.2 +/- 19.3% and 79.4 +/- 27.8%, respectively. By contrast, total occlusion remained in group C. The ejection fraction measured four weeks later was slightly greater in group B than in group C, and was significantly greater in group A than in group C. If the average ages and complications of the other coronary vessels were considered, a significant difference was recognized among these three groups. The amplitude of the anterior wall motion of the patients with anterior infarction in each group assessed by a point score system was significantly increased in groups A and B as compared to group C. Peak CPK, GOT and LDH rose rapidly immediately after reperfusion and the time interval from the onset of symptoms to peak enzyme production was significantly shortened after reperfusion. These data supported the following concept: 1) coronary thrombus formation frequently occurs in acute myocardial infarction and can be rapidly lysed by IC infusion of UK with a total dose of 250,000 to 600,000 units, 2) reperfusion by lysis of IC thrombi in patients with acute myocardial infarction improves left ventricular wall motion, 3) peak enzyme rises rapidly after reperfusion, 4) the time interval from the onset of symptoms to peak enzyme production is remarkably shortened after repeat perfusion and that 5) no fatal arrhythmia nor bleeding are recognized. Thus, IC infusion of UK in the early stage of acute myocardial infarction was effective and useful.
 ...
PMID:[Intracoronary thrombolysis in acute myocardial infarction]. 653 93

A woman with mixed connective tissue disease (MCTD) developed pulmonary hypertension after delivery of a child, but had little evidence of parenchymal lung disease. This 29-year-old woman had been given a diagnosis of MCTD when she was 19 years old. She was admitted to our department two days after delivery of a child, because of dyspnea on exertion. Acute thromboembolism was suspected because of: (1) chest roentgenogram showing cardiomegaly and enlargement of the left main pulmonary artery, (2) a lung perfusion scan showing a segmental defect in the left S6 and S8 areas, (3) laboratory studies showing abnormally high WBC, LDH, FDP, and D-D dimer, and (4) arterial blood gas analyses showing mild hypoxemia and hypocapnia. Thrombolytic therapy with heparin and urokinase was begun, and was followed by a loop diurtic and anticoagulation with warfarin. One month after admission, cardiac enlargement and the A-aDO2 were found to have decreased. At that time, cardiac catheterization was done and revealed pulmonary hypertension (mean PA pressure: 45 mmHg) and low cardiac output with no detectable thrombosis in the left pulmonary artery. The patient was subsequently treated with a calcium antagonist and a prostacyclin derivative, and her condition was stable for 5 months. Then her exercise tolerance gradually decreased due to shortness of breath, and cardiomegaly gradually increased over the next 3 months. Eight months after delivery of the child, the patient died of right heart failure. In clinically stable patients with MCTD, delivery of a child may lead to pulmonary thromboembolism and pulmonary hypertension.
 ...
PMID:[Puerperal secondary pulmonary hypertension in a patient with mixed connective tissue disease]. 747 71

The effect of sodium pentosan polysulphate (SPP) was investigated in calcium oxalate stone forming rats with respect to the urinary excretion of certain risk factors and enzymes. Calcium oxalate stones were induced by feeding 3% w/w sodium glycollate to the rats. Urinary calcium, oxalate, phosphorus and uric acid levels were increased in stone formers. In contrast magnesium excretion was low in this group. SPP treatment lowered oxalate and calcium levels in both controls and experimental animals. Magnesium levels were increased moderately. Increased excretion of urinary enzymes--LDH, alkaline phosphatase, gamma-GT and beta glucuronidase--in calculogenic rats indicates membranuria and damage to proximal tubules during stone formation. Decreased pyrophosphatase activity was observed in glycollate fed rats. SPP treatment decreased the excretion of the above enzymes in the treated groups. Stone formers exhibited decreased LAP and fibrinolytic (urokinase) activities. SPP being associated with fibrinolytic properties, increased the activities of the above two enzymes to that of control levels in calculogenic rats.
 ...
PMID:Alterations in some risk factors and urinary enzymes in urolithiatic rats treated with sodium pentosan polysulphate. 768 93

The lung plasminogen activator (PA) response was examined in four different models of particle-induced pulmonary lesions in NMRI mice (single intratracheal administration, 0.75 to 5 mg/mouse). Sequential changes in cellular (total and differential counts) and biochemical markers of alveolitis (lactate dehydrogenase [LDH], total proteins) were monitored in bronchoalveolar fluid (BALF) and the fibrotic lung response was assessed histologically. An intense but spontaneously resolving alveolitis was produced by manganese dioxide (MnO2) and a fibrosing alveolitis was elicited by crystalline silica (DQ12). Minimal and noninflammatory responses were obtained after instillation of titanium dioxide (TiO2) and tungsten carbide (WC), respectively. The comparison between the resolving and the fibrosing alveolitis model was especially taken into consideration in an attempt to identify fibrinolytic changes associated with the development of fibrosis. At the alveolitis stage, similarly increased BALF PA activities were measured in both the resolving and the fibrosing alveolitis models whereas only slight and no PA modifications were noted after administration of TiO2 and WC, respectively. Persistently (up to 120 d) increased BALF PA activity was selectively associated with the progression to fibrosis (DQ12), suggesting that PA is involved in the fibrotic process. ELISA measurements demonstrated that the changes in BALF PA activity were exclusively related to changes in urokinase (uPA), not tissue-type PA. A rapid and persisting (up to Day 30) upregulation of cell-associated PA activity occurred after DQ12, MnO2, and TiO2 treatment only. Cellular PA activity was however significantly higher in fibrogenic inflammatory cells recovered from DQ12 than from MnO2-treated mice suggesting that the intensity of cellular PA upregulation may represent an early indicator of the progression to fibrosis. The implication of urokinase in the pathogenesis of silica-induced fibrosis was demonstrated by the use of a uPA knockout mice. The acceleration of the fibrotic process in uPA-deficient compared with the wild type animals demonstrated the contribution of uPA to limit the fibrotic process.
 ...
PMID:Role of urokinase in the fibrogenic response of the lung to mineral particles. 947 81

A 55-year-old woman affected by mitralism presented with severe right flank pain of sudden onset. Biochemical examinations showed elevated serum lactate dehydrogenase, and abdominal enhanced computed tomography (CT) demonstrated hypoperfusion of the right kidney. Infarction of the right kidney was highly suspected, and she was immediately treated by systemic intravenous injection of 12,000,000 units of tissue plasminogen activator (tPA) per day for 3 days and 120,000 units of urokinase per day for 8 days. After the thrombolytic therapy, abdominal enhanced CT revealed marked improvement of enhancement of right renal parenchyma and decrease of serum LDH. Although thrombolytic therapy with selective intraarterial infusion is considered to be a useful treatment modality for renal infarction, systemic administration of tPA may also be effective judging from the clinical course of the present case.
 ...
PMID:[A case of renal infarction treated by thrombolytic therapy with systemic intravenous injection of tPA (tissue plasminogen activator)]. 1224 75

Cathepsins S and H are present in immune cells and tissues and may play a role in the activation of an adoptive immune response. Our goal was to assess their protein levels in pleural fluids from 82 patients who underwent thoracentesis or thoracoscopy for therapeutic or diagnostic reasons and to relate them to an inflammatory, neoplastic or hemodynamic origin. Pleural effusions were also analyzed for a panel of 13 inflammatory or proliferative markers to test possible links to a nonspecific host reaction. Increased levels of cathepsin S were found in parainflammatory and cancer-related effusions compared to transudates. Cathepsin H levels were elevated only in parainflammatory effusions, whereas the levels in cancer-related effusions were comparable to transudates. Cathepsin S values significantly correlated with LDH, alpha-1-AT, VEGF, sICAM, sVCAM, MPO, uPA, MMP-9/TIMP-1, IL-8 and MCP-1, but not with CRP, IL-10 or cathepsin H. In contrast to cathepsin S, cathepsin H values did not correlate with markers of inflammation, indicating a specific role for cathepsin H in the pleural host response. In conclusion, the estimation of cathepsin S and cathepsin H may help to distinguish between effusions of different etiology.
 ...
PMID:Levels of cathepsins S and H in pleural fluids of inflammatory and neoplastic origin. 1940 22


1 2 Next >>